<DOC>
	<DOCNO>NCT01068977</DOCNO>
	<brief_summary>This Phase I , open label , dose-escalation study MetMAb administer intravenous ( IV ) infusion patient advance solid malignancy refractory standard care . The study consist dose-escalation stage , expansion stage test MetMAb recommend Phase II dose ( RP2D ) , dose-escalation stage test combination MetMAb , two different dos bevacizumab recommend dose .</brief_summary>
	<brief_title>A Study Safety Pharmacology MetMAb ( PRO143966 ) , Monovalent Antagonist Antibody Receptor C-Met , Administered Intravenously Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic documentation incurable , locally advanced , metastatic solid malignancy fail respond least one prior regimen standard therapy Disease measurable evaluable Response Evaluation Criteria In Solid Tumors ( RECIST ) Life expectancy ≥12 week Less 4 week since last anti‑tumor therapy Patients receive erythropoietin product Active infection require antibiotic Active autoimmune disease control nonsteroidal anti‑inflammatory drug Symptomatic hypercalcemia require continue use bisphosphonate therapy Clinically important history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Primary central nervous system ( CNS ) malignancy , untreated/active CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>